-
公开(公告)号：US20120214809A1
公开(公告)日：2012-08-23
申请号：US13400039
申请日：2012-02-18
申请人： Scott Kevin Thompson , Tony Priestley , Roger Astbury Smith , Ashis K. Saha , Sonali Rudra , Arun Kuma Hajra , Dipanwita Chatterjee , Carl Henry Behrens , Yigang He , Hui-Yin Li
发明人： Scott Kevin Thompson , Tony Priestley , Roger Astbury Smith , Ashis K. Saha , Sonali Rudra , Arun Kuma Hajra , Dipanwita Chatterjee , Carl Henry Behrens , Yigang He , Hui-Yin Li
IPC分类号： A61K31/452 , C07D207/09 , A61K31/40 , C07D401/12 , A61K31/4545 , A61K31/506 , C07D417/12 , A61K31/454 , C07D498/10 , A61K31/5386 , C07D405/12 , A61K31/453 , C07D471/10 , A61K31/438 , A61P29/00 , A61P17/04 , C07D211/26
CPC分类号： C07D211/26 , A61K31/167 , A61K31/40 , A61K31/452 , A61K45/06 , C07D207/09 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12 , C07D471/10 , C07D498/10 , A61K2300/00
摘要： The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV 1 receptor activator. In one embodiment, the TRPV 1 receptor activator is lidocaine.
摘要翻译： 本申请提供了新的氨基茚满化合物以及制备和使用这些化合物的方法。 这些化合物可用于通过向患者施用一种或多种化合物来治疗患者的疼痛和/或瘙痒。 所述方法包括施用式（I）或（II）化合物和TRPV 1受体激活剂。 在一个实施方案中，TRPV 1受体激活剂是利多卡因。
-
公开(公告)号：US20080076750A1
公开(公告)日：2008-03-27
申请号：US11854738
申请日：2007-09-13
申请人： Robert Aslanian , Tin-Yau Chan , Joel Harris , Brian McKittrick , Bernard Neustadt , Anandan Palani , Tony Priestley , Elizabeth Smith , Andrew Stamford , Henry Vaccaro , Dong Xiao
发明人： Robert Aslanian , Tin-Yau Chan , Joel Harris , Brian McKittrick , Bernard Neustadt , Anandan Palani , Tony Priestley , Elizabeth Smith , Andrew Stamford , Henry Vaccaro , Dong Xiao
IPC分类号： A61K31/397 , A61P25/04 , A61P3/00
CPC分类号： A61K31/4427 , C07D471/10 , C07D519/00
摘要： The present invention relates to methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering a compound having the formula or a pharmaceutically acceptable salt, solvate, ester, prodrug or stereoisomer thereof, wherein: R1 and R2 are defined in Tables 1-6 herein, and R3 is -phenyl, -4-chlorophenyl, -2-pyridyl, or -3-pyridyl.
摘要翻译： 本发明涉及治疗或预防脂质代谢紊乱，疼痛，糖尿病，血管病症，脱髓鞘或非酒精性脂肪性肝病的方法，包括给予具有下式的化合物或其药学上可接受的盐，溶剂合物，酯，前药或 其中：R 1和R 2在本文的表1-6中定义，R 3是 - 苯基， 氯苯基，-2-吡啶基或-3-吡啶基。
-
3.发明申请Compositions and methods for short interfering nucleic acid inhibition of NAv1.8 有权NAv1.8短干扰核酸抑制的组成和方法公开(公告)号：US20060199779A1
公开(公告)日：2006-09-07
申请号：US11259588
申请日：2005-10-26
申请人： Sameer Goregaoker , John Hunter , Tony Priestley
发明人： Sameer Goregaoker , John Hunter , Tony Priestley
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/111 , C12N2310/14
摘要： The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
摘要翻译： 本发明提供短干扰核酸，单链或双链，其引起RNAi诱导的来自Na + 1.8钠通道基因的mRNA的降解; 涉及包含这种短干扰核酸的药物组合物; 包含这种短干扰核酸的重组载体; 抑制mRNA翻译的方法; 抑制多肽表达的方法; 阻断细胞膜电位的方法; 阻止细胞中钠电流的方法; 和抑制慢性疼痛的方法。
-
公开(公告)号：US20060014794A1
公开(公告)日：2006-01-19
申请号：US11126977
申请日：2005-05-11
申请人： Jianhua Chao , Arthur Taveras , Cynthia Aki , Daniel Lundell , Jay Fine , Tony Priestley , Angelo Reggiani
发明人： Jianhua Chao , Arthur Taveras , Cynthia Aki , Daniel Lundell , Jay Fine , Tony Priestley , Angelo Reggiani
IPC分类号： A61K31/454
CPC分类号： C07D333/36 , C07D207/34 , C07D207/36 , C07D231/38 , C07D231/46 , C07D275/03 , C07D277/54 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/12
摘要： The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
摘要翻译： 本发明涉及具有式（1）的通式结构的化合物：可用于治疗，预防或改善CXCR1或CXCR2趋化因子介导的疾病。
-
5.发明授权Compositions and methods for short interfering nucleic acid inhibition of Nav1.8 有权Nav1.8短干扰核酸抑制的组成和方法公开(公告)号：US07786291B2
公开(公告)日：2010-08-31
申请号：US11259588
申请日：2005-10-26
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/111 , C12N2310/14
摘要： The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
摘要翻译： 本发明提供短链干扰核酸，单链或双链，其导致RNAi诱导的来自Nav1.8钠通道基因的mRNA降解; 涉及包含这种短干扰核酸的药物组合物; 包含这种短干扰核酸的重组载体; 抑制mRNA翻译的方法; 抑制多肽表达的方法; 阻断细胞膜电位的方法; 阻止细胞中钠电流的方法; 和抑制慢性疼痛的方法。
-
公开(公告)号：US08865741B2
公开(公告)日：2014-10-21
申请号：US13400039
申请日：2012-02-18
申请人： Scott Kevin Thompson , Tony Priestley , Roger Astbury Smith , Ashis K. Saha , Sonali Rudra , Arun Kuma Hajra , Dipanwita Chatterjee , Carl Henry Behrens , Yigang He , Hui-Yin Li
发明人： Scott Kevin Thompson , Tony Priestley , Roger Astbury Smith , Ashis K. Saha , Sonali Rudra , Arun Kuma Hajra , Dipanwita Chatterjee , Carl Henry Behrens , Yigang He , Hui-Yin Li
IPC分类号： A61K31/445 , C07D211/26
CPC分类号： C07D211/26 , A61K31/167 , A61K31/40 , A61K31/452 , A61K45/06 , C07D207/09 , C07D401/12 , C07D403/12 , C07D405/12 , C07D417/12 , C07D471/10 , C07D498/10 , A61K2300/00
摘要： The present application provides novel aminoindane compounds and methods for preparing and using these compounds. These compounds are useful in treating pain and/or itch in patients by administering one or more of the compounds to a patient. The methods include administering a compound of formula (I) or (II) and a TRPV1 receptor activator. In one embodiment, the TRPV1 receptor activator is lidocaine.
摘要翻译： 本申请提供了新的氨基茚满化合物以及制备和使用这些化合物的方法。 这些化合物可用于通过向患者施用一种或多种化合物来治疗患者的疼痛和/或瘙痒。 所述方法包括施用式（I）或（II）的化合物和TRPV1受体激活剂。 在一个实施方案中，TRPV1受体激活剂是利多卡因。
-
7.发明申请COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF NAV1.8 有权短期干扰NAV1.8的核酸抑制剂的组合物和方法公开(公告)号：US20100305192A1
公开(公告)日：2010-12-02
申请号：US12789564
申请日：2010-05-28
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/111 , C12N2310/14
摘要： The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
摘要翻译： 本发明提供短链干扰核酸，单链或双链，其导致RNAi诱导的来自Nav1.8钠通道基因的mRNA降解; 涉及包含这种短干扰核酸的药物组合物; 包含这种短干扰核酸的重组载体; 抑制mRNA翻译的方法; 抑制多肽表达的方法; 阻断细胞膜电位的方法; 阻止细胞中钠电流的方法; 和抑制慢性疼痛的方法。
-
公开(公告)号：US20070248594A1
公开(公告)日：2007-10-25
申请号：US11775567
申请日：2007-07-10
申请人： Jianhua Chao , Arthur Taveras , Cynthia Aki , Daniel Lundell , Jay Fine , Tony Priestley , Angelo Reggiani
发明人： Jianhua Chao , Arthur Taveras , Cynthia Aki , Daniel Lundell , Jay Fine , Tony Priestley , Angelo Reggiani
IPC分类号： A61K31/381 , A61K31/4015 , A61K31/4025 , A61K31/4152 , A61K31/425 , A61K31/4436 , A61K31/497 , A61K31/5355 , A61K31/675 , A61K31/70 , A61K31/727 , A61K39/395 , C07D207/36 , C07D241/04 , C07D275/03 , C07D333/36 , C07D409/12 , C07D413/12
CPC分类号： C07D333/36 , C07D207/34 , C07D207/36 , C07D231/38 , C07D231/46 , C07D275/03 , C07D277/54 , C07D409/04 , C07D409/12 , C07D409/14 , C07D417/12
摘要： The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
摘要翻译： 本发明涉及具有式（1）的通式结构的化合物：可用于治疗，预防或改善CXCR1或CXCR2趋化因子介导的疾病。
-
9.发明申请COMPOSITIONS AND METHODS FOR SHORT INTERFERING NUCLEIC ACID INHIBITION OF Nav 1.8 审中-公开组合物和方法用于短暂干扰核酸的抑制作用公开(公告)号：US20140256787A1
公开(公告)日：2014-09-11
申请号：US14258391
申请日：2014-04-22
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/111 , C12N2310/14
摘要： The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Na.sub.v1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
摘要翻译： 本发明提供短链干扰核酸，单链或双链，其引起RNAi诱导的来自Na.sv1.8钠通道基因的mRNA的降解; 涉及包含这种短干扰核酸的药物组合物; 包含这种短干扰核酸的重组载体; 抑制mRNA翻译的方法; 抑制多肽表达的方法; 阻断细胞膜电位的方法; 阻止细胞中钠电流的方法; 和抑制慢性疼痛的方法。
-
10.发明授权Compositions and methods for short interfering nucleic acid inhibition of Nav1.8 有权Nav1.8短干扰核酸抑制的组成和方法公开(公告)号：US08309703B2
公开(公告)日：2012-11-13
申请号：US12789564
申请日：2010-05-28
CPC分类号： C12N15/113 , C12N15/1138 , C12N2310/111 , C12N2310/14
摘要： The invention provides short interfering nucleic acids, either single-stranded or double-stranded, that cause RNAi-induced degradation of mRNA from the Nav1.8 sodium channel gene; to pharmaceutical compositions comprising such short interfering nucleic acids; recombinant vectors comprising such short interfering nucleic acids; a method for inhibiting translation of an mRNA; a method for inhibiting expression of a polypeptide; a method for blocking the membrane potential in a cell; a method for blocking the sodium current in a cell; and a method for inhibiting chronic pain.
摘要翻译： 本发明提供短链干扰核酸，单链或双链，其导致RNAi诱导的来自Nav1.8钠通道基因的mRNA降解; 涉及包含这种短干扰核酸的药物组合物; 包含这种短干扰核酸的重组载体; 抑制mRNA翻译的方法; 抑制多肽表达的方法; 阻断细胞膜电位的方法; 阻止细胞中钠电流的方法; 和抑制慢性疼痛的方法。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.021 秒)
